CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Open accessThe DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index, and 2 are not checked yet; 10 of the 45 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroinflammation, and cerebrovascular changes and study their associations with the core biomarkers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging correlates, and clinical disease progression over time. METHODS: The study included cognitively unimpaired elderly (n = 508), patients with mild cognitive impairment (MCI, n = 256), and patients with AD dementia (n = 57) from the longitudinal Swedish BioFINDER cohort. CSF samples were analyzed for YKL-40, interleukin (IL)-6, IL-7, IL-8, IL-15, IP-10, monocyte chemoattractant protein 1, intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), placental growth factor, and fms-related tyrosine kinase 1 (Flt-1). MRI data were available from 677 study participants. Longitudinal clinical assessments were conducted in control individuals and patients with MCI (mean follow-up 3 years, range 1-6 years). RESULTS: CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased during the preclinical, prodromal, and dementia stages of AD. High levels of these biomarkers were associated with increased CSF levels of total tau, with the associations, especially for YKL-40, being stronger in Aβ-positive individuals. The results were similar for associations between phosphorylated tau and YKL-40, ICAM-1, and VCAM-1. High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions) and with subsequent cognitive deterioration in patients without dementia as measured with Mini-Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40, ICAM-1, VCAM-1 and IL-15). Finally, higher levels of CSF YKL-40, ICAM-1, and Flt-1 increased risk of development of AD dementia in patients without dementia. CONCLUSIONS: Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression.
Verified 2026-10-05 · 2 references not checked yet
Overview
CoChat Summary
TL;DR
In the Swedish BioFINDER cohort, CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were elevated in preclinical, prodromal, and dementia stages of Alzheimer disease and were associated with tau pathology, cortical thinning, cognitive decline, and progression to AD dementia. The authors conclude that neuroinflammation and cerebrovascular dysfunction are early events in AD that may contribute to disease progression.
Key findings
- Pathologic Aβ status was associated with higher CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 (all p < 0.001) in both control and MCI groups; these biomarkers were increased in control–Aβ+, MCI–Aβ+, and AD dementia groups compared with control–Aβ−, but not in MCI–Aβ−.
- Higher CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were associated with higher t-tau and p-tau; interactions with Aβ status were significant for t-tau (YKL-40 p < 0.001; ICAM-1 p = 0.040; VCAM-1 p = 0.002; IL-15 p = 0.043; Flt-1 p = 0.001) and for p-tau with YKL-40 (p < 0.001), ICAM-1 (p = 0.024), and VCAM-1 (p = 0.011).
- Higher biomarker levels were associated with cortical thinning primarily in precuneus and superior parietal regions; YKL-40 was associated with reduced left and right caudate and left amygdala volumes (β = −0.092, p = 0.036; β = −0.124, p < 0.001; β = −0.102, p = 0.030; false discovery rate–adjusted p values).
- In participants without dementia, higher YKL-40 was associated with lower baseline MMSE and faster MMSE decline; YKL-40, VCAM-1, and IL-15 were associated with higher baseline CDR-SB, and YKL-40, ICAM-1, VCAM-1, and IL-15 with faster CDR-SB increase. Among 728 followed participants, 115 (15.8%) progressed to AD dementia; highest tertiles of YKL-40 (p = 0.005), ICAM-1 (p = 0.001), and Flt-1 (p = 0.007) were associated with increased risk.
Methods
- Longitudinal Swedish BioFINDER cohort: 508 cognitively unimpaired elderly (315 cognitively normal plus 193 with subjective cognitive decline), 256 patients with MCI, and 57 patients with AD dementia; MRI data were available for 677 participants after quality control; longitudinal clinical assessments in controls and MCI had mean follow-up 3 years (range 1–6 years).
- CSF was analyzed for 11 neuroinflammatory and cerebrovascular biomarkers (YKL-40, IL-6, IL-7, IL-8, IL-15, IP-10, MCP-1, ICAM-1, VCAM-1, PlGF, Flt-1) using Mesoscale Discovery immunoassay and ELISA for YKL-40, Aβ42, Aβ40, t-tau, and p-tau; Aβ status was defined by CSF Aβ42/Aβ40 ratio cutoff ≤0.1.
- Analyses included ANOVA/GLM with Bonferroni correction, linear regression, linear mixed-effects models for longitudinal MMSE and CDR-SB, Cox proportional hazards models for time to AD dementia, and voxel-wise/region-of-interest MRI analyses with false discovery rate correction at q = 0.05; models adjusted for age, sex, and APOE genotype, with anti-inflammatory medications considered in initial analyses.
Limitations
- The paper does not include a formal limitations section. The authors note considerable overlap in CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 between groups, suggesting AD may be accompanied by neuroinflammation and cerebrovascular dysfunction in a subpopulation of patients, and state that future longitudinal assessments of biomarker levels are warranted.
- Evident from the text: the study is observational, and the reported associations cannot establish causality; the authors describe the processes as possibly contributing to tau pathology, neurodegeneration, atrophy, and AD risk.
- Evident from the text: several analyses and data are reported as available from Dryad rather than fully in the main paper, and the cohort is from the Swedish BioFINDER study with follow-up averaging 3 years (range 1–6 years), which may limit generalizability and long-term inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 CSF biomarkers of neuroinflammation and cerebrovascular changes, CSF tau, and cortical atrophy (A, B) Association between CSF YKL-40 and total tau (t-tau) and CSF YKL-40 and phosphorylated tau (p-tau), respectively, in study participants with normal (β-amyloid [Aβ]−) and pathologic (Aβ+) CSF status. Unstandardized B coefficients and p values for slopes are from linear regression models. The results were very similar when adjusting for the covariates (age, sex, APOE ε4 genotype, and anti-inflammatory medications). (C) Associations between YKL-40 and cortical thickness. Voxel-wise regression analysis corrected for age, sex, and APOE ε4.](https://figures.cochat.ai/paper-figures/cd07b07684484dbf9878d9a65db23188/csf-biomarkers-of-neuroinflammation-and-cerebrovascular-dysfunction-in-early-figure-2.jpg)

Verification
Claims the paper makes
8 Valid · 0 Not valid · 20 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“At the same, studies have indicated that Aβ pathology may lead to secondary vascular damage including white matter lesions, microinfarcts, and microbleeds.12”
§ CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease > Abstract > Conclusions
What the sources say
- Supportedcites [12] Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke 2009; 40: 2601– 2606. 19443808 PMC2704252 source
The Cerebral amyloid angiopathy section links Aβ-related CAA to white matter lesions and microinfarctions. The Alzheimer’s disease section reports microbleeds associated with CAA, while the Conclusions describe vascular damage from Aβ deposits and propose a mechanism for microinfarcts. Together, these support the claim’s cautious wording. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“AD is also associated with cerebrovascular changes that have been implicated in neuronal dysfunction and neurodegeneration.9”
§ CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease > Abstract > Conclusions
What the sources say
- Supportedcites [9] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723– 738. 22048062 PMC4036520 source
The Vascular pathology section reports cerebrovascular changes in patients with Alzheimer’s disease. The section “Does vascular dysfunction cause neuronal dysfunction?” links vascular dysfunction to neuronal dysfunction and secondary neurodegeneration, consistent with the claim’s cautious wording. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Earlier investigations that have measured CSF and blood levels of ICAM-1, VCAM-1, and IL-15 in AD have produced conflicting results.38–42”
§ CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease > Discussion
What the sources say
- Not checked yetcites [38] Huang CW, Tsai MH, Chen NC, et al. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia. Thromb Haemost 2015; 114: 1230– 1240. 26289958 source
- Partly supportedcites [39] Johansson P, Almqvist EG, Wallin A, et al. Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. PLoS One 2017; 12: e0176760. 28464009 PMC5413050 sourceExperimental — accuracy not yet measured
Our copy of Johansson et al. (2017) supports only the IL-15 part of the claim: the Discussion states that 'circulating or CSF concentrations of IL-8, IL-15, IL-16, and VEGF have been decreased [31, 32], unchanged [12, 33–35], or increased [34, 36–39] in AD', i.e. conflicting results in AD across blood and CSF. However, the paper never mentions ICAM-1 or VCAM-1: its multiplex panel (Biochemical procedures; Abstract Methods) measured only IL-6, IL-8, IL-12/23 p40, IL-15, IL-16, VEGF-A, IP-10, MCP-1 and MIP-1β, and Table 1 reports no adhesion molecules. Searches for 'ICAM-1', 'VCAM-1' and 'cell adhesion molecule' returned no passage in our copy, so that portion of the compound claim is not attributable to this source. (LLM, conf=0.75)
- Not checked yetcites [40] Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 2007; 26: 27– 35. 17270454 source
- Not checked yetcites [41] Rentzos M, Michalopoulou M, Nikolaou C, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 2005; 228: 129– 135. 15694193 source
- Not checked yetcites [42] Rentzos M, Zoga M, Paraskevas GP, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006; 19: 114– 117. 16690997 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two earlier reports have found that YKL-40 predicted progression to AD.22,49”
§ CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease > Discussion
What the sources say
- Partly supportedcites [22] Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010; 68: 903– 912. 21035623 PMC3011944 sourceExperimental — accuracy not yet measured
The Results section, “Ability of CSF YKL-40 To Predict Onset and Progression of Dementia” (page unavailable), reports that the CSF YKL-40/Aβ42 ratio predicted conversion from normal cognition to cognitive impairment. It does not establish that YKL-40 alone predicted progression to AD: individual YKL-40 performed less well, and the ratio’s association with progression from CDR 0.5 to CDR>0.5 did not reach statistical significance. (LLM, conf=0.87)
- Supportedcites [49] Kester MI, Teunissen CE, Sutphen C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther 2015; 7: 59. 26383836 PMC4574487 source
The Results section (‘Predictive value of baseline levels of biomarkers for progression of MCI to symptomatic AD’) reports that baseline CSF YKL-40 predicted progression from MCI to AD. This supports the finding attributed to this report; the cited paper alone does not establish what the other report found. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions)”
§ CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 100 claims and to verify the 35 references still open.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 29
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“there is biomarker evidence of stronger correlations between the glial activation biomarker YKL-40 and soluble tau in people with Aβ pathology, compared with people without Aβ pathology (31).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [31]
In the citing paper
“While YKL40 is also elevated in other neurodegenerative disorders including AD, 80 , 81 sAPPβ concentrations were specifically lower in FTLD syndromes.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [81]
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“AD is accompanied by activation of microglia and astrocytes(1,2) that affects the clearance and production of Aβ42,(3,4) development and propagation of tau pathology,(5) exacerbates neurodegeneration, and influences disease progression and severity.(6,7) Genome-wide association studies have identified several single n…”
BackgroundVEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationNeuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“AD is accompanied by activation of microglia and astrocytes(1,2) that affects the clearance and production of Aβ42,(3,4) development and propagation of tau pathology,(5) exacerbates neurodegeneration, and influences disease progression and severity.(6,7) Genome-wide association studies have identified several single n…”
BackgroundDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Research works printed but not linked: 1
- Team RC. R: language and environment for statistical computing. In: R Foundation for Statistical Computing. Vienna, Austria: 2014. Available at: r-project.org/. Accessed September 17, 2016.
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Self-citationMattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359
“In line with this hypothesis, there is biomarker evidence of stronger correlations between the glial activation biomarker YKL-40 and soluble tau in people with A pathology, compared with people without A pathology (31).”
Self-citationPalmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
“YKL-40 concentrations were measured using ELISA kits according to the manufacturer’s recommendations (YKL-40 R&D Systems, Inc., Minneapolis, MN, USA) (Janelidze et al, 2018).”
MethodSelf-citationMultiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0795-2 · Cited by 262
Self-citation
Metadata
- Authors
- Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Hansson, Oskar
- ORCID
- Venue
- Neurology
- Published
- 2018-08-28
- Volume
- 91
- Issue
- 9
- Pages
- e867-e877
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC6133624
- OpenAlex
- W2883326166
- Cited by
- 359
- References
- 48
- Citations by year
- 2026: 29 · 2025: 53 · 2024: 65 · 2023: 40 · 2022: 40 · 2021: 60 · 2020: 46 · 2019: 23 · 2018: 2
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Neurology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Marcus Foundation
- Vetenskapsrådet
- Marcus och Amalia Wallenbergs minnesfond
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, neuroinflammation, cerebrovascular dysfunction, YKL-40, ICAM-1, VCAM-1, IL-15, Flt-1, microglial activation, astrocyte activation, amyloid-beta, tau protein, mild cognitive impairment, cortical thinning, cognitive decline, disease progression
- MeSH terms
- Chitinase-3-Like Protein 1, Placenta Growth Factor, Aged, Aged, 80 and over, Cerebrovascular Disorders, Encephalitis, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Biomarkers, Cytokines, Amyloid beta-Peptides, tau Proteins, Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, Vascular Endothelial Growth Factor Receptor-1, Apolipoprotein E4, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000006082
- The paper
- Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018). CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000006082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.